Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.34 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449227 | 1.00 | POLB (0.41) | POLBGRIK1GRIK2SLC16A3SLC16A1 | |
| SCHEMBL11442710 | 1.00 | POLB (0.41) | POLBGRIK1GRIK2SLC16A3SLC16A1 | |
| SCHEMBL2401988 | 0.98 | GRIK1 (0.40) | POLBGRIK1GRIK2SLC16A3SLC16A1 | |
| SCHEMBL15156069 | 0.90 | EGFR (0.37) | POLBSLC16A3SLC16A1CISD1KDM4E | |
| SCHEMBL13857888 | 0.90 | EGFR (0.37) | POLBSLC16A3SLC16A1CISD1KDM4E | |
| SCHEMBL11102084 | 0.90 | EGFR (0.37) | POLBSLC16A3SLC16A1CISD1KDM4E | |
| SCHEMBL26080805 | 0.82 | EGFR (0.33) | POLBSLC16A3SLC16A1CISD1KDM4E | |
| SCHEMBL19194988 | 0.79 | POLB (0.34) | POLB | |
| SCHEMBL4892042 | 0.78 | APP (0.36) | POLBKDM4EALDH1A1CYP3A4HPGD | |
| SCHEMBL24243317 | 0.77 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366721-B1 | Medical kit for use during negative pressure wound therapy | AESCULAP AG (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2366721-A1 | Medical kit for use during negative pressure wound therapy | AESCULAP AG (DE) | 2011-09-21 | — | — | EP | disclosed |
| US-20100035997-A1 | KIT FOR APPLYING A POLYMERIZABLE ADHESIVE COMPOSITION TO TISSUES | BROADLEY KENNETH N | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035997-A1 | KIT FOR APPLYING A POLYMERIZABLE ADHESIVE COMPOSITION TO TISSUES | KIT, TEKT1, CUTA | POLB 1476/4885GRIK1 2306/4885GRIK2 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.